Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma-Reference-Cited by-同舟云学术

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

Published:2014-04-03 Issue:7 Volume:63 Page:675-683
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Simeone Ester,Gentilcore Giusy,Giannarelli Diana,Grimaldi Antonio M.,Caracò Corrado,Curvietto Marcello,Esposito Assunta,Paone Miriam,Palla Marco,Cavalcanti Ernesta,Sandomenico Fabio,Petrillo Antonella,Botti Gerardo,Fulciniti Franco,Palmieri Giuseppe,Queirolo Paola,Marchetti Paolo,Ferraresi Virginia,Rinaldi Gaetana,Pistillo Maria Pia,Ciliberto Gennaro,Mozzillo Nicola,Ascierto Paolo A.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s00262-014-1545-8.pdf

Reference31 articles.

1. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723

2. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE et al (2012) CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 18:2039–2047

3. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507–2516

4. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358–365

5. Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P et al (2013) MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 14:249–256

Cited by 226 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Peripheral blood cytokines and outcomes with immune checkpoint blockade: a systematic review and meta-analysis;Immunotherapy;2024-08-19

2. Treatment response of advanced HNSCC towards immune checkpoint inhibition is associated with an activated effector memory T cell phenotype;Frontiers in Oncology;2024-03-07

3. High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcome;Therapeutic Advances in Medical Oncology;2024-01

4. Role of biomarkers in assessing response to immune checkpoint inhibitors in cancer treatment;Biomarkers in Cancer Detection and Monitoring of Therapeutics;2024

5. Investigation of response factors for monotherapy with immune checkpoint inhibitors in non‐small cell lung cancer patients with PD‐L1 expression <50%;Thoracic Cancer;2023-08-03